A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD
Status:
Completed
Trial end date:
2016-12-27
Target enrollment:
Participant gender:
Summary
The phase 2 study will evaluate the safety, tolerability and efficacy of HLD100 at steady
state (following up to 5 weeks of treatment) in children using an outpatient, single-center,
open-label, flexible dose-escalation study design.